Skip to main content
Premium Trial:

Request an Annual Quote

SeqWright to Handle DNA Screening/Genotyping for Third Wave's HPV Trials

NEW YORK (GenomeWeb News) — SeqWright today said it will perform all of the sequencing and analysis for a set of clinical trials being conducted by Third Wave Technologies.
 
Third Wave is developing two in vitro molecular assays and a genotyping test to screen for human papillomavirus, which has been identified as the cause of approximately 70 percent of cervical cancer cases, SeqWright said.
 
Third Wave’s tests will detect and identify 14 HPV high-risk types and HPV types 16 and 18, the company said.   
 
SeqWright uses gene sequencing and bioinformatics technologies to help companies run clinical trials for FDA submission.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.